Chromadex (NASDAQ:CDXC) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Earnings and Valuation

This table compares Chromadex and Cronos Group’s gross revenue, earnings per share and valuation.

Cronos Group has lower revenue, but higher earnings than Chromadex. Chromadex is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Chromadex and Cronos Group’s net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Chromadex and Cronos Group, as reported by MarketBeat.

Chromadex currently has a consensus target price of $8.00, suggesting a potential upside of 125.35%. Cronos Group has a consensus target price of $6.75, suggesting a potential downside of 26.23%. Given Chromadex’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Chromadex is more favorable than Cronos Group.

Institutional & Insider Ownership

16.6% of Chromadex shares are held by institutional investors. Comparatively, 10.6% of Cronos Group shares are held by institutional investors. 10.3% of Chromadex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cronos Group beats Chromadex on 7 of the 12 factors compared between the two stocks.